Project description
Multitargeting strategy to overcome cancer therapy resistance
Cancer onset and development is affected by many parameters, including genetics, the environment, and epigenetic factors. As such, compounds that simultaneously target multiple epigenetic enzymes may be a promising therapeutic strategy to overcome cancer therapy resistance. Using this premise, the EU-funded EpiPolyPharma project is developing novel molecules to target protein methylation and acetylation (common in epigenetic pathways). In particular, the researchers are investigating enzymes that cooperate in different pathways simultaneously to counteract tumour growth. As the most promising inhibitors will be assessed in cell assays and for their effects on the regulation of cancer gene transcription, the project foresees additional personalised weapons to combat cancer and related drug resistance.
Fields of science
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesclinical medicineoncology
- natural sciencesbiological sciencesbiophysics
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
MSCA-PF -Coordinator
00185 Roma
Italy
See on map
Partners (1)
27100 Pavia
See on map